Aim Defects in hepatic glycogen synthesis contribute to postprandial hyperglycemia in type 2 diabetic (T2D) patients. Chromogranin A (CgA) peptide Catestatin (CST: hCgA_352-372) has been shown to improve glucose tolerance in insulin-resistant mice. Here, we seek to determine whether CST also reduces hyperglycemia by increasing hepatic glycogen synthesis.

中文翻译：

---

Catestatin 通过刺激磷酸肌醇 3-激酶-AKT 通路诱导糖生成

目的肝糖原合成缺陷导致 2 型糖尿病 (T2D) 患者餐后高血糖。已显示嗜铬粒蛋白 A (CgA) 肽 Catestatin（CST：hCgA _352-372）可改善胰岛素抵抗小鼠的葡萄糖耐量。在这里，我们试图确定 CST 是否也通过增加肝糖原合成来降低高血糖。